AngioDynamics' NanoKnife System Shows Durable Results in Prostate Cancer Trial
Event summary
- AngioDynamics reported 24-month data from the PRESERVE trial showing 94.4% of patients completed the assessment with no new treatment failures.
- 97% of patients had PSA levels below baseline at 24 months, and no new device- or procedure-related adverse events were reported.
- The trial involved 121 patients with intermediate-risk prostate cancer across 17 U.S. clinical centers.
- Results will be presented at the 2026 AUA Annual Meeting by Izak Faiena, M.D., of Columbia University.
The big picture
AngioDynamics' positive 24-month data for the NanoKnife System reinforces its position in the growing market for minimally invasive prostate cancer treatments. The results align with broader industry trends toward personalized and less invasive cancer therapies, potentially expanding the company's reach in urologic oncology. The sustained efficacy and safety profile could drive greater physician and patient adoption, but scaling reimbursement and competition remain key challenges.
What we're watching
- Clinical Adoption
- How quickly physicians will integrate the NanoKnife System into standard care for intermediate-risk prostate cancer.
- Reimbursement Infrastructure
- Whether AngioDynamics can expand reimbursement coverage to make the NanoKnife System more accessible.
- Market Competition
- The pace at which competitors develop similar focal therapy options for prostate cancer.
Related topics